UPCC 19520: An Open-Label Multi-Institutional Pilot Study to Assess The Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate

Brief description of study

This study is being done to answer the following question: Does scheduled glucarpidase reduce the levels of methotrexate in patients blood and lead to shorter hospitalizations and a reduction in toxicities? Eligible subjects will be those with osteosarcoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 10 Feb 2021. Study ID: 844853

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).